Rahul Basu
Yerkes National Primate Research Center
13 Papers
145 Citations
Rahul Basu is an academic researcher from Yerkes National Primate Research Center. The author has contributed to research in topics: Modified vaccinia Ankara & Virus. The author has an hindex of 9, co-authored 11 publications. Previous affiliations of Rahul Basu include Emory University.
Chat about Author
Papers
A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model
Aaron C. Brault,Arban Domi,Erin M. McDonald,Dalit Talmi-Frank,Nathanael McCurley,Rahul Basu,Harriet L. Robinson,Michael Hellerstein,Nisha K. Duggal,Richard A. Bowen,Farshad Guirakhoo +10 more
TL;DR: The development of an alternative vaccine strategy encompassing the expression of ZIKV non-structural-1 (NS1) protein from a clinically proven safe, Modified Vaccinia Ankara (MVA) vector is described, thus averting the potential risk of ADE associated with structural protein-based ZikV vaccines.
A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge
Arban Domi,Friederike Feldmann,Rahul Basu,Nathanael McCurley,Kyle Shifflett,Jackson Emanuel,Michael Hellerstein,Farshad Guirakhoo,Chiara Orlandi,Robin Flinko,George K. Lewis,Patrick W. Hanley,Heinz Feldmann,Harriet L. Robinson,Andrea Marzi +14 more
TL;DR: This is the first report that a replication-deficient MVA vector can confer full protection against lethal EBOV challenge after a single dose vaccination in macaques.
Diminished Viral Control during Simian Immunodeficiency Virus Infection Is Associated with Aberrant PD-1hi CD4 T Cell Enrichment in the Lymphoid Follicles of the Rectal Mucosa
Geetha H. Mylvaganam,Geetha H. Mylvaganam,Vijayakumar Velu,Vijayakumar Velu,Jung Joo Hong,Jung Joo Hong,Shanmugalakshmi Sadagopal,Shanmugalakshmi Sadagopal,Suefen Kwa,Suefen Kwa,Rahul Basu,Rahul Basu,Benton Lawson,Francois Villinger,Francois Villinger,Rama Rao Amara,Rama Rao Amara +16 more
TL;DR: In this article, a subset of CD4 T cells expressed high levels of PD-1 (PD-1(hi)) in the rectal mucosa, a preferential site of virus replication.
47
DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus
Melanie A. Thompson,Sonya L. Heath,Bentley Sweeton,Kathy S. Williams,Pamela Cunningham,Brandon F. Keele,Sharon Sen,Brent E. Palmer,Nicolas Chomont,Yongxian Xu,Rahul Basu,Michael Hellerstein,Suefen Kwa,Harriet L. Robinson +13 more
TL;DR: It is hypothesized that escape mutations, already archived in the viral reservoir, plus a poor ability of CD8+ T cells to traffic to and control virus at sites of re-emergence, limited the therapeutic efficacy of the DNA/MVA vaccine.
CD40L-Adjuvanted DNA/Modified Vaccinia Virus Ankara Simian Immunodeficiency Virus (SIV) Vaccine Enhances Protection against Neutralization-Resistant Mucosal SIV Infection
Suefen Kwa,Shanmugalakshmi Sadagopal,Xiaoying Shen,Jung Joo Hong,Sailaja Gangadhara,Rahul Basu,Blandine Victor,Smita S. Iyer,Celia C. LaBranche,David C. Montefiori,Georgia D. Tomaras,Francois Villinger,Bernard Moss,Pamela A. Kozlowski,Rama Rao Amara +14 more
TL;DR: It is shown that a CD40L-adjuvanted DNA/modified vaccinia virus Ankara (MVA) simian immunodeficiency virus (SIV) vaccine enhances protection against a pathogenic neutralization-resistant mucosal SIV infection, improves long-term viral control, and prevents AIDS.
31